Budgetary impact of diagnostic tests for visceral leishmaniasis in Brazil

Detalhes bibliográficos
Autor(a) principal: Assis,Tália Santana Machado de
Data de Publicação: 2017
Outros Autores: Azeredo-da-Silva,André Luís Ferreira de, Oliveira,Diana, Cota,Gláucia, Werneck,Guilherme Loureiro, Rabello,Ana
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Cadernos de Saúde Pública
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2017001205013
Resumo: Abstract: The aim of the present study was to estimate the financial costs of the incorporation and/or replacement of diagnostic tests for human visceral leishmaniasis (VL) in Brazil. The analysis was conducted from the perspective of the Brazilian Unified National Health System (SUS) over a period of three years. Six diagnostic tests were evaluated: the indirect immunofluorescence antibody test (IFAT), the IT LEISH rapid test, the parasitological examination of bone marrow aspirate, the direct agglutination test (DAT-LPC) standardized in the Clinical Research Laboratory, René Rachou Institute of the Oswaldo Cruz Foundation, the Kalazar Detect rapid test, and polymerase chain reaction (PCR). The assumptions used were the number of suspected cases of VL reported to the Brazilian Ministry of Health in 2014 and the direct cost of diagnostic tests. The costs to diagnose suspected cases of VL over three years using the IFAT and the DAT-LPC were estimated at USD 280,979.91 and USD 121,371.48, respectively. The analysis indicated that compared with the use of the IFAT, the incorporation of the DAT-LPC into the SUS would result in savings of USD 159,608.43. With regard to the budgetary impact of rapid tests, the use of IT LEISH resulted in savings of USD 21.708,72 over three years. Compared with a parasitological examination, diagnosis using PCR resulted in savings of USD 3,125,068.92 over three years. In this study, the replacement of the IFAT with the DAT-LPC proved financially advantageous. In addition, the replacement of the Kalazar Detect rapid test with the IT LEISH in 2015 was economically valuable, and the replacement of parasitological examination with PCR was indicated.
id FIOCRUZ-5_1faff4d56d3960bce977e4e3736da4e9
oai_identifier_str oai:scielo:S0102-311X2017001205013
network_acronym_str FIOCRUZ-5
network_name_str Cadernos de Saúde Pública
repository_id_str
spelling Budgetary impact of diagnostic tests for visceral leishmaniasis in BrazilBudgetary ControlVisceral LeishmaniasisDiagnosisAbstract: The aim of the present study was to estimate the financial costs of the incorporation and/or replacement of diagnostic tests for human visceral leishmaniasis (VL) in Brazil. The analysis was conducted from the perspective of the Brazilian Unified National Health System (SUS) over a period of three years. Six diagnostic tests were evaluated: the indirect immunofluorescence antibody test (IFAT), the IT LEISH rapid test, the parasitological examination of bone marrow aspirate, the direct agglutination test (DAT-LPC) standardized in the Clinical Research Laboratory, René Rachou Institute of the Oswaldo Cruz Foundation, the Kalazar Detect rapid test, and polymerase chain reaction (PCR). The assumptions used were the number of suspected cases of VL reported to the Brazilian Ministry of Health in 2014 and the direct cost of diagnostic tests. The costs to diagnose suspected cases of VL over three years using the IFAT and the DAT-LPC were estimated at USD 280,979.91 and USD 121,371.48, respectively. The analysis indicated that compared with the use of the IFAT, the incorporation of the DAT-LPC into the SUS would result in savings of USD 159,608.43. With regard to the budgetary impact of rapid tests, the use of IT LEISH resulted in savings of USD 21.708,72 over three years. Compared with a parasitological examination, diagnosis using PCR resulted in savings of USD 3,125,068.92 over three years. In this study, the replacement of the IFAT with the DAT-LPC proved financially advantageous. In addition, the replacement of the Kalazar Detect rapid test with the IT LEISH in 2015 was economically valuable, and the replacement of parasitological examination with PCR was indicated.Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz2017-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2017001205013Cadernos de Saúde Pública v.33 n.12 2017reponame:Cadernos de Saúde Públicainstname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZ10.1590/0102-311x00142416info:eu-repo/semantics/openAccessAssis,Tália Santana Machado deAzeredo-da-Silva,André Luís Ferreira deOliveira,DianaCota,GláuciaWerneck,Guilherme LoureiroRabello,Anaeng2018-04-24T00:00:00Zoai:scielo:S0102-311X2017001205013Revistahttp://cadernos.ensp.fiocruz.br/csp/https://old.scielo.br/oai/scielo-oai.phpcadernos@ensp.fiocruz.br||cadernos@ensp.fiocruz.br1678-44640102-311Xopendoar:2018-04-24T00:00Cadernos de Saúde Pública - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.none.fl_str_mv Budgetary impact of diagnostic tests for visceral leishmaniasis in Brazil
title Budgetary impact of diagnostic tests for visceral leishmaniasis in Brazil
spellingShingle Budgetary impact of diagnostic tests for visceral leishmaniasis in Brazil
Assis,Tália Santana Machado de
Budgetary Control
Visceral Leishmaniasis
Diagnosis
title_short Budgetary impact of diagnostic tests for visceral leishmaniasis in Brazil
title_full Budgetary impact of diagnostic tests for visceral leishmaniasis in Brazil
title_fullStr Budgetary impact of diagnostic tests for visceral leishmaniasis in Brazil
title_full_unstemmed Budgetary impact of diagnostic tests for visceral leishmaniasis in Brazil
title_sort Budgetary impact of diagnostic tests for visceral leishmaniasis in Brazil
author Assis,Tália Santana Machado de
author_facet Assis,Tália Santana Machado de
Azeredo-da-Silva,André Luís Ferreira de
Oliveira,Diana
Cota,Gláucia
Werneck,Guilherme Loureiro
Rabello,Ana
author_role author
author2 Azeredo-da-Silva,André Luís Ferreira de
Oliveira,Diana
Cota,Gláucia
Werneck,Guilherme Loureiro
Rabello,Ana
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Assis,Tália Santana Machado de
Azeredo-da-Silva,André Luís Ferreira de
Oliveira,Diana
Cota,Gláucia
Werneck,Guilherme Loureiro
Rabello,Ana
dc.subject.por.fl_str_mv Budgetary Control
Visceral Leishmaniasis
Diagnosis
topic Budgetary Control
Visceral Leishmaniasis
Diagnosis
description Abstract: The aim of the present study was to estimate the financial costs of the incorporation and/or replacement of diagnostic tests for human visceral leishmaniasis (VL) in Brazil. The analysis was conducted from the perspective of the Brazilian Unified National Health System (SUS) over a period of three years. Six diagnostic tests were evaluated: the indirect immunofluorescence antibody test (IFAT), the IT LEISH rapid test, the parasitological examination of bone marrow aspirate, the direct agglutination test (DAT-LPC) standardized in the Clinical Research Laboratory, René Rachou Institute of the Oswaldo Cruz Foundation, the Kalazar Detect rapid test, and polymerase chain reaction (PCR). The assumptions used were the number of suspected cases of VL reported to the Brazilian Ministry of Health in 2014 and the direct cost of diagnostic tests. The costs to diagnose suspected cases of VL over three years using the IFAT and the DAT-LPC were estimated at USD 280,979.91 and USD 121,371.48, respectively. The analysis indicated that compared with the use of the IFAT, the incorporation of the DAT-LPC into the SUS would result in savings of USD 159,608.43. With regard to the budgetary impact of rapid tests, the use of IT LEISH resulted in savings of USD 21.708,72 over three years. Compared with a parasitological examination, diagnosis using PCR resulted in savings of USD 3,125,068.92 over three years. In this study, the replacement of the IFAT with the DAT-LPC proved financially advantageous. In addition, the replacement of the Kalazar Detect rapid test with the IT LEISH in 2015 was economically valuable, and the replacement of parasitological examination with PCR was indicated.
publishDate 2017
dc.date.none.fl_str_mv 2017-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2017001205013
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2017001205013
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0102-311x00142416
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz
publisher.none.fl_str_mv Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz
dc.source.none.fl_str_mv Cadernos de Saúde Pública v.33 n.12 2017
reponame:Cadernos de Saúde Pública
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Cadernos de Saúde Pública
collection Cadernos de Saúde Pública
repository.name.fl_str_mv Cadernos de Saúde Pública - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv cadernos@ensp.fiocruz.br||cadernos@ensp.fiocruz.br
_version_ 1754115738075922432